BridgeBio turns Alexion asset into first approved drug for rare metabolic disease

The FDA decision makes Nulibry the first drug approved to treat MoCD type A, a rare metabolic disease. It’s also the first FDA-approved product for rare disease drug developer BridgeBio Pharma.